

Maximizing use of available population-based data on cardiometabolic diseases

Global Health & Population Project on Access to Care for Cardiometabolic Diseases (HPACC)

DOI:

[10.1016/S2213-8587\(21\)00328-4](https://doi.org/10.1016/S2213-8587(21)00328-4)

License:

Creative Commons: Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)

Document Version

Peer reviewed version

Citation for published version (Harvard):

Global Health & Population Project on Access to Care for Cardiometabolic Diseases (HPACC) 2022, 'Maximizing use of available population-based data on cardiometabolic diseases', *The Lancet Diabetes and Endocrinology*. [https://doi.org/10.1016/S2213-8587\(21\)00328-4](https://doi.org/10.1016/S2213-8587(21)00328-4)

[Link to publication on Research at Birmingham portal](#)

General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

1 **Maximizing Use of Available Population-Based Data on Cardiometabolic Diseases**

2
3 David Flood¹⁻³, David Guwatudde⁴, Albertino Damasceno⁵⁻⁷, Jennifer Manne-Goehler^{8,9*}, Justine
4 I. Davies^{10-12*}, for the Global Health & Population Project on Access to Care for Cardiometabolic
5 Diseases (HPACC)[†]

6
7 ¹Division of Hospital Medicine, Department of Medicine, University of Michigan, Ann Arbor,
8 Michigan, USA; ²Center for Indigenous Health Research, Wuqu' Kawoq, Tecpán, Guatemala;
9 ³Research Center for the Prevention of Chronic Diseases, Institute of Nutrition of Central
10 America and Panama, Guatemala City, Guatemala; ⁴Department of Epidemiology and
11 Biostatistics, School of Public Health, Makerere University, Kampala, Uganda; ⁵Department of
12 Public and Forensic Health Sciences and Medical Education, Faculty of Medicine, University of
13 Porto, Porto, Portugal; ⁶EPIUnit, Institute of Public Health, University of Porto, Porto, Portugal;
14 ⁷Faculty of Medicine, Eduardo Mondlane University, Maputo, Mozambique; ⁸Division of
15 Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA,
16 USA; ⁹Medical Practice Evaluation Center, Massachusetts General Hospital, Harvard Medical
17 School, Boston, MA, USA; ¹⁰Institute for Applied Health Research, University of Birmingham,
18 UK; ¹¹Centre for Global Surgery, Department of Global Health, Stellenbosch University, Cape
19 Town, South Africa; ¹²Medical Research Council/Wits University Rural Public Health and Health
20 Transitions Research Unit, Faculty of Health Sciences, School of Public Health, University of the
21 Witwatersrand, Johannesburg, South Africa

22
23 *Joint senior authors

24 [†]Members listed at end of paper

25

26 Corresponding author:
27 [Justine I. Davies](#), MD
28 Institute ~~for~~of Applied Health Research
29 University of Birmingham
30 Birmingham, United Kingdom
31 B15 2TT
32 J.davies.6@bham.ac.uk
33
34 Word count: [907947](#)
35 References: 10

36 The absolute worldwide burden of adult cardiometabolic diseases such as hypertension,
37 diabetes, obesity, and dyslipidemia continues its relentless ascent. Scaling up ~~the~~ prevention,
38 management, and control of cardiometabolic diseases is cost-effective but requires strong
39 health systems.¹⁴ Building ~~thesestrong health systems~~ requires data that are accurate, timely,
40 and transparent, as we have previously argued in this journal.² In particular, data from high-
41 quality population-based surveys are critical, as they reflect the spectrum of community-dwelling
42 adults ~~in a particular geography~~, including those who are not reached by the health system.

43
44 ~~There~~Of late, ~~there~~ has been tremendous progress in making population-based survey data
45 available for cardiometabolic diseases. Emblematic of this has been the release in 2018 of the
46 World Health Organization (WHO) Noncommunicable Disease (NCD) Microdata Repository.³
47 This hosts over 130 surveys conducted using the STEPwise approach to NCD surveillance
48 (STEPS) methodology that are now available ~~after to users who submit~~ a brief application. Most
49 STEPS surveys are conducted in low- and middle-income countries (LMICs) where a majority of
50 the cardiometabolic disease burden occurs. Thus, this resource fills a critical gap in openly
51 accessible population-based survey data on cardiometabolic risk factors and health care access
52 in these settings.

53
54 Yet, there is more work to be done. The availability of population-based data, while necessary,
55 is insufficient ~~by itself~~ to ensure their effective use to shape programs, strategies, and policies
56 addressing cardiometabolic diseases. In this Comment, we highlight three other crucial actions
57 ~~needed~~ to maximize the use of population data: harmonization, alignment with monitoring
58 indicators to benchmark health system performance, and capacity-building initiatives to
59 democratize data use ([figure](#)).

60

61 Our perspective is informed by our experience in the Global Health and Population Project on
62 Access to Care for Cardiometabolic diseases (HPACC), an international research consortium
63 with collaborators in more than 30 countries. ~~HPACC has created a dynamic repository of~~
64 ~~harmonized, nationally representative survey data currently~~ representing 1.3 million individuals
65 ~~in more than 75 LMICs (including more than 50 STEPS surveys.) to address questions of~~
66 ~~relevance to health system planning and evaluation for cardiometabolic diseases.~~

67
68 First, while population-based data ~~can and~~ should be used at the national level, these data also
69 should be harmonized to maximize ~~its~~ use by international advocacy organizations,
70 policymakers, and researchers. Harmonization refers to the process of bringing together distinct
71 data sources into a single comparable format. Harmonized survey data are available in the area
72 of maternal and child health,⁴ but no such resource exists for cardiometabolic diseases. Such
73 harmonized data allows for assessing health system effectiveness ~~and responsiveness~~, as our
74 study of the state of hypertension care in 44 LMICs illustrates.⁵⁵ Harmonization ~~also~~ provides
75 larger and more diverse samples, giving added power to study variations in cardiometabolic risk
76 factors, including biological measures such as blood glucose and behavioral risk factors such as
77 physical activity and diet. Understanding these variations is important, as it cannot be assumed
78 that epidemiologic patterns of clinical relevance observed in well-studied high-income countries
79 will be conserved in LMICs. Indeed, we have found that the association between diabetes and
80 body mass index (BMI) is highly variable across world regions, implying that BMI thresholds
81 generated using European or North American data cannot simply be applied ~~elsewhere in other~~
82 ~~world regions.~~⁶ ~~Harmonization also allows for the construction of sophisticated clinical and policy~~
83 ~~models for the prevention, treatment, and control of cardiometabolic diseases to predict effects~~
84 ~~of change.~~^{1,76} Importantly, to ensure that data are useful for cross-country comparisons, prior to
85 data collection, time should be spent ensuring survey instruments and data collection are
86 standardized and aligned with the highest priority global health metrics.

87

88 Second, population data on cardiometabolic diseases should be harnessed to benchmark and
89 monitor health system performance. At present, these data are underutilized for this purpose.

90 Harmonized data from STEPS and ~~similar~~ ~~non-STEPS~~ surveys can reveal progress on monitoring indicators
91 in the NCD Global Monitoring Framework⁷ and inform new targets such as those proposed by
92 the WHO Global Diabetes Compact, a recently established initiative to improve global diabetes
93 care.⁸⁸ To show global variation in health system performance, harmonized data ideally should
94 include not only LMICs but also high-income countries, though unfortunately data from high-
95 income countries are currently less available.

96

97 Third, given limited research capacity in many LMICs, there is a need to build capacity to ensure
98 the wide usability of population data on cardiometabolic diseases, ~~most especially~~ by those who have collected
99 it. Local researchers—especially those in LMICs—who design and conduct surveys should be
100 empowered to use harmonized data to answer their policy-relevant questions, conduct
101 independent analyses, and publish in lead-author roles.⁹ In addition to this being a step towards
102 decolonialization of global health, these collaborators add critical contextual interpretation that
103 may not be fully perceived or appreciated by those outside their settings.

104 maximizing use of available population data on cardiometabolic diseases, it is important to
105 continue data-sharing efforts. Many STEPS and comparable ~~non-STEPS~~ household surveys remain
106 unavailable, as are more than two dozen nationally representative health facility surveys
107 conducted using the WHO Service Availability Readiness Assessment (SARA) methodology.¹⁰
108 Additionally, many other data sources, for example, from subnational research studies, remain
109 inaccessible. Finally, cardiometabolic disease epidemiology is rapidly evolving, but data are
110 often historical. As ~~is done~~ for HIV, data collection for cardiometabolic diseases needs to be ongoing to
111 assess temporal trends in disease prevalence and health system performance.

112

113 While we focus on maximizing use of available population data on cardiometabolic diseases, it
114 is important to continue data-sharing efforts. Many STEPS and comparable ~~non-STEPS~~
115 household surveys remain unavailable, as are more than two dozen nationally representative
116 health facility surveys conducted using the WHO Service Availability Readiness Assessment
117 (SARA) methodology.¹⁰ Additionally, many other data sources, for example, from subnational
118 research studies, remain inaccessible. Finally, cardiometabolic disease epidemiology is rapidly
119 evolving, but data are often historical. As ~~is done~~ for HIV, data collection for cardiometabolic
120 diseases needs to be ongoing to assess temporal trends in disease prevalence and health
121 system performance.

122

123 The staggering burden of cardiometabolic diseases brings ~~with it~~ an imperative to maximize the use of
124 these data. Many countries and individuals ~~LMICs already~~ have invested substantial resources
125 in producing these data, which are a global public good. However, while they are increasingly
126 available, in practice ~~they~~ these data are still too sparse and underutilized given the toll these
127 diseases are taking on people worldwide. We call on funders and international health
128 organizations to invest in efforts to collect, harmonize and make available these data with an
129 urgency befitting the magnitude of the global burden of cardiometabolic diseases.

130

131 **Declaration of interests**

132 DF reports grant funding within the 3 years from a Pilot and Feasibility Grant funded by the
133 Michigan Center for Diabetes Translational Research (NIH Grant P30-DK092926) and a grant
134 from the Swinmurn Foundation to implement a sustainable diabetes clinic in Guatemala. DF
135 also reports volunteer affiliations with Wugu' Kawoq and GlucoSalud, outside the submitted
136 work. During the course of this work, DF has received research fellowship funding from National
137 Clinician Scholars Program at the University of Michigan Institute for Healthcare Policy &
138 Innovation. TB reports grants from the Alexander von Humboldt Foundation, Wellcome Trust,
139 and U.S. National Institutes of Health. RA reports contracts with Novo Nordisk, Union for
140 International Cancer Control's (UICC), Novo Nordisk, Hoffman-La Roche, and Sloan Memorial
141 Kettering Hospital, outside the submitted work. RA also reports payments or honorario from
142 Merck and Hoffmann-La Roche, outside the submitted work. All other authors declare no
143 competing interests.

144
145
146 **References**

- 147 1. Basu S, Flood D, Geldsetzer P, et al. Estimated impact of increased diagnosis,
148 treatment, and control of diabetes mellitus among low-and middle-income countries: A
149 microsimulation model. *Lancet Global Health* 2021; (Accepted; in press).
- 150 2. Davies J, Yudkin JS, Atun R. Liberating data: the crucial weapon in the fight against
151 NCDs. *Lancet Diabetes Endocrinol* 2016; 4(3): 197-8.
- 152 3. World Health Organization. NCD Microdata Repository. 2021.
153 <https://extranet.who.int/ncdsmicrodata/index.php/catalog> (accessed July 19, 2021).
- 154 4. IPUMS. IPUMS Global Health. 2021. <https://globalhealth.ipums.org/> (accessed October
155 25, 2021).

- 156 5. Geldsetzer P, Manne-Goehler J, Marcus ME, et al. The state of hypertension care in 44
157 low-income and middle-income countries: a cross-sectional study of nationally representative
158 individual-level data from 1.1 million adults. *Lancet* 2019; 394(10199): 652-62.
- 159 6. Teufel F, Seiglie JA, Geldsetzer P, et al. Body-mass index and diabetes risk in 57 low-
160 income and middle-income countries: a cross-sectional study of nationally representative,
161 individual-level data in 685 616 adults. *Lancet* 2021; 398(10296): 238-48.
- 162 7. WHO. Noncommunicable Diseases Global Monitoring Framework: Indicator Definitions
163 and Specifications. 2014. [https://www.who.int/nmh/ncd-](https://www.who.int/nmh/ncd-tools/indicators/GMF_Indicator_Definitions_Version_NOV2014.pdf)
164 [tools/indicators/GMF_Indicator_Definitions_Version_NOV2014.pdf](https://www.who.int/nmh/ncd-tools/indicators/GMF_Indicator_Definitions_Version_NOV2014.pdf) (accessed September 29,
165 2021).
- 166 8. Hunt D, Hemmingsen B, Matzke A, et al. The WHO Global Diabetes Compact: a new
167 initiative to support people living with diabetes. *Lancet Diabetes Endocrinol* 2021; 9(6): 325-7.
- 168 9. Wang W, Assaf S, Pullum T, Kishor S. The Demographic and Health Surveys Faculty
169 Fellows Program: Successes, Challenges, and Lessons Learned. *Glob Health Sci Pract* 2021;
170 9(2): 390-8.
- 171 10. Mangipudi S, Leather A, Seedat A, Davies J. Oxygen availability in sub-Saharan African
172 countries: a call for data to inform service delivery. *The Lancet Global Health* 2020; 8(9): e1123-
173 e4.
174
175

176 **HPACC members**

177
178 David Flood¹⁻³, David Guwatudde⁴, Albertino Damasceno⁵⁻⁷, Krishna K. Aryal⁸, Rifat Atun^{9,10}, Till
179 W. Bärnighausen¹¹⁻¹³, Brice Wilfried Bicaba¹⁴, Pascal Bovet^{15,16}, Gary Brian¹⁷, Maria
180 Dorobantu¹⁸, Farshad Farzadfar¹⁹, Gladwell Gathecha²⁰, Pascal Geldsetzer^{11,21}, Mongal Singh
181 Gurung²², Corine Houehanou²³, Nahla Hwalla²⁴, Lindsay Jaacks²⁵, Jutta Jorgensen²⁶, Gibson
182 Kagaruki²⁷, Khem Karki²⁸, Demetre Labadarios²⁹, Nuno Lunet^{5,30}, Maja E. Marcus³¹, Joao
183 Martins³², Mary Mayige²⁷, Omar Mwalim^{33,34}, Kibachio Joseph Mwangi^{20,35}, Bolormaa Norov³⁶,
184 Rebekka Rühle³¹, Sahar Saeedi Moghaddam³⁷, Jacqueline A. Seiglie³⁸, Abla M. Sibai³⁹,
185 Bahendeka Karaireho Silver⁴⁰, Andrew Stokes⁴¹, Lela Sturua⁴², Adil Supiyev⁴³, Michaela
186 Theilmann¹¹, Lindiwe Tsabedze⁴⁴, Sebastian Vollmer³¹, Kehinde D. Whyte-Ilori⁴⁵, Zhaxybay
187 Zhumadilov⁴⁶, Jennifer Manne-Goehler^{47,48}, Justine I. Davies⁴⁹⁻⁵¹

188
189 **Affiliations**

190
191 ¹Division of Hospital Medicine, Department of Medicine, University of Michigan, Ann Arbor,
192 Michigan, USA; ²Center for Indigenous Health Research, Wuqu' Kawoq, Tecpán, Guatemala;
193 ³Research Center for the Prevention of Chronic Diseases, Institute of Nutrition of Central
194 America and Panama, Guatemala City, Guatemala; ⁴Department of Epidemiology and
195 Biostatistics, School of Public Health, Makerere University, Kampala, Uganda; ⁵Department of
196 Public and Forensic Health Sciences and Medical Education, Faculty of Medicine, University of
197 Porto, Porto, Portugal; ⁶EPIUnit, Institute of Public Health, University of Porto, Porto, Portugal;
198 ⁷Faculty of Medicine, Eduardo Mondlane University, Maputo, Mozambique; ⁸Monitoring
199 Evaluation and Operational Research Project, Abt Associates, Kathmandu, Nepal; ⁹Department
200 of Global Health and Population, Harvard T.H. Chan School of Public Health, Harvard
201 University, Boston, MA, USA; ¹⁰Department of Global Health and Social Medicine, Harvard
202 Medical School, Harvard University, Boston, MA, USA; ¹¹Heidelberg Institute of Global Health,
203 Heidelberg University, Heidelberg, Germany; ¹²Africa Health Research Institute, Somkhele,
204 South Africa; ¹³Harvard Center for Population and Development Studies, Cambridge, USA;
205 ¹⁴Institut National de Santé Publique, Burkina Faso; ¹⁵Ministry of Health, Victoria, Seychelles;
206 ¹⁶Institute of Social and Preventive Medicine, Lausanne, Switzerland; ¹⁷The Fred Hollows
207 Foundation New Zealand; ¹⁸University of Medicine and Pharmacy Carol Davila, Bucharest,
208 Romania; ¹⁹Non-Communicable Diseases Research Center, Endocrinology and Metabolism
209 Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran; ²⁰Division of
210 Non-Communicable Diseases, Ministry of Health, Nairobi, Kenya; ²¹Division of Primary Care
211 and Population Health, Stanford University; ²²Health Research and Epidemiology Unit, Ministry
212 of Health, Thimphu, Bhutan; ²³Laboratory of Epidemiology of Chronic and Neurological
213 Diseases, Faculty of Health Sciences, University of Abomey-Calavi, Cotonou, Benin; ²⁴Faculty
214 of Agricultural and Food Sciences, American University of Beirut, Beirut, Lebanon; ²⁵Global
215 Academy of Agriculture and Food Security, The University of Edinburgh, Midlothian, United
216 Kingdom; ²⁶Department of Public Health, University of Copenhagen, Copenhagen, Denmark;
217 ²⁷National Institute for Medical Research, Dar es Salaam, Tanzania; ²⁸Department of
218 Community Medicine and Public Health, Institute of Medicine, Tribhuvan University, Kathmandu,
219 Nepal; ²⁹Faculty of Medicine and Health Sciences, Stellenbosch University, Stellenbosch, South
220 Africa; ³⁰EPIUnit Institute of Public Health, University of Porto, Porto, Portugal; ³¹Department of
221 Economics and Centre for Modern Indian Studies, University of Göttingen, Göttingen, Germany;
222 ³²Faculty of Medicine and Health Sciences, National University of East Timor, Dili, Timor-Leste;
223 ³³Ministry of Health and Social Welfare, Elderly, Gender and Children, Zanzibar, Tanzania;
224 ³⁴Bergen Centre for Ethics and Priority Setting (BCEPS), Department of Global Public Health
225 and Primary Care, University of Bergen, Norway; ³⁵Faculté de Médecine, Université de Genève,
226 Geneva, Switzerland; ³⁶National Center for Public Health, Ulaanbaatar, Mongolia;

227 ³⁷Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical
228 Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran; ³⁸Diabetes Unit,
229 Massachusetts General Hospital, Boston, United States of America; ³⁹Epidemiology and
230 Population Health Department, Faculty of Health Sciences American University of Beirut, Beirut,
231 Lebanon; ⁴⁰Uganda Martyrs University | Saint Francis Hospital Nsambya, Kampala, Uganda;
232 ⁴¹Department of Global Health, Boston University School of Public Health, Boston, United
233 States of America; ⁴²Non-Communicable Disease Department, National Center for Disease
234 Control and Public Health, Tbilisi, Georgia; ⁴³Laboratory of Epidemiology and Public Health,
235 Center for Life Sciences, Nazarbayev University, Astana, Kazakhstan; ⁴⁴Ministry of Health,
236 Mbabane, Eswatini; ⁴⁵School of Medicine, University of Leeds, Leeds, West Yorkshire, United
237 Kingdom; ⁴⁶Nazarbayev University School of Medicine, Nur-Sultan, Kazakhstan; ⁴⁷Division of
238 Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA,
239 USA; ⁴⁸Medical Practice Evaluation Center, Massachusetts General Hospital, Harvard Medical
240 School, Boston, MA, USA; ⁴⁹Institute for Applied Health Research, University of Birmingham,
241 UK; ⁵⁰Centre for Global Surgery, Department of Global Health, Stellenbosch University, Cape
242 Town, South Africa; ⁵¹Medical Research Council/Wits University Rural Public Health and Health
243 Transitions Research Unit, Faculty of Health Sciences, School of Public Health, University of the
244 Witwatersrand, Johannesburg, South Africa;"
245